01 March 2005 : Original article
Correlation between acoustic speech characteristics and non-speech motor performance in Parkinson DiseaseAlexander M. Goberman
Med Sci Monit 2005; 11(3): CR109-116 :: ID: 15386
Background: Research has found that non-speech motor defi cits in Parkinson Disease (PD) can be consistently improved by levodopa medications and surgical treatment, but that speech and voice are only
partially responsive to treatment. This has led to the assertion that speech is an axial (non-peripheral) feature of PD, along with other features that are only partially responsive to treatment (e.g., postural stability and gait). The current study tested this assertion via examination of the relationship between multiple measures of speech production and multiple measures of non-speech movement in individuals with PD.
Material/Methods: Nine individuals with idiopathic PD were studied, and all participants were taking levodopa-carbidopa medication. Motor performance was examined using the motor portion of the Unifi ed
Parkinson’s Disease Rating Scale, and speech was examined via acoustic analysis of phonation, articulation, and prosody.
Results: Seven of sixteen speech acoustic measures (F[sub]o[/sub]SD in vowels, F2 slope for /u/ and /æ/, F[sub]o[/sub]SD in reading, articulation rate in monologue, and percent pause in reading and monologue) were signifi - cantly correlated with non-speech movements. Results suggested that speech measures are correlated with both axial motor symptoms (e.g., gait, facial expression, posture, postural stability) and
non-axial motor symptoms (e.g., rest tremor, left and right bradykinesia, postural tremor).
Conclusions: It has been hypothesized that axial symptoms of PD are more purely dopaminergic, and non-axial symptoms are related to non-dopaminergic lesions. Therefore, the current results indicate that
certain speech defi cits in PD may result from dopaminergic lesions, while others appear to result from non-dopaminergic lesions.
Keywords: Carbidopa - pharmacology, Carbidopa - therapeutic use, Gait - drug effects, Motor Skills Disorders - complications, Aged, 80 and over, Antiparkinson Agents - therapeutic use, Carbidopa - therapeutic use, Deep Brain Stimulation, Gait - drug effects, Levodopa - therapeutic use, Motor Skills, Motor Skills Disorders - physiopathology, Parkinson Disease - physiopathology, Severity of Illness Index, Speech Acoustics, Time Factors
01 December 2021 : EditorialEditorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
Med Sci Monit 2021; 27:e935624
03 December 2021 : Laboratory ResearchInfluenza and Influenza-Like Respiratory Virus Infections in Children During the 2019/20 Influenza Season a...
Med Sci Monit In Press; DOI: 10.12659/MSM.934862
08 November 2021 : Database AnalysisVirtual Screening and Molecular Docking to Study the Mechanism of Chinese Medicines in the Treatment of Cor...
Med Sci Monit In Press; DOI: 10.12659/MSM.934102
01 November 2021 : EditorialEditorial: What Can be Learned from National and International Vaccine Adverse Event Reporting Systems Duri...
Med Sci Monit 2022; 28:e935299
06 Dec 2021 : Animal ResearchAstragalus Flavone Induces Proliferation and Differentiation of Neural Stem Cells in a Cerebral Infarction ...
Med Sci Monit In Press; DOI: 10.12659/MSM.933830
06 Dec 2021 : Clinical ResearchAlteration of Serum Metabolites in Women of Reproductive Age with Chronic Constipation
Med Sci Monit In Press; DOI: 10.12659/MSM.934117
06 Dec 2021 : Clinical ResearchBody Composition Changes and Related Factors in Patients with Ulcerative Colitis: A Retrospective Single-Ce...
Med Sci Monit In Press; DOI: 10.12659/MSM.933942
Most Viewed Current Articles
20 Mar 2020 : Clinical ResearchSocial Capital and Sleep Quality in Individuals Who Self-Isolated for 14 Days During the Coronavirus Diseas...
Med Sci Monit 2020; 26:e923921
15 Apr 2020 : Clinical ResearchPsychological Impact and Coping Strategies of Frontline Medical Staff in Hunan Between January and March 20...
Med Sci Monit 2020; 26:e924171
05 May 2020 : Review articleAn Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development
Med Sci Monit 2020; 26:e924700